Department of Pharmaceutics, University of London, London WC1N 1AX, UK.
Int J Pharm. 2011 Sep 15;416(1):55-60. doi: 10.1016/j.ijpharm.2011.05.079. Epub 2011 Jun 14.
Poorly water soluble basic drugs are very sensitive to pH changes and following dissolution in the acidic stomach environment tend to precipitate upon gastric emptying, which leads to compromised or erratic oral bioavailability. In this work, we show that the oral bioavailability of a model poorly soluble basic drug (cinnarizine) can be improved by drug encapsulation within highly pH-responsive microparticles (Eudragit L). The latter was prepared by emulsion solvent evaporation which yielded discrete spherical microparticles (diameter of 56.4±6.8μm and a span of 1.2±0.3). These Eudragit L (dissolution threshold pH 6.0) microparticles are expected to dissolve and release their drug load at intestinal conditions. Thus, the enteric microparticles inhibited the in vitro release of drug under gastric conditions, despite high cinnarizine solubility in the acidic medium. At intestinal conditions, the particles dissolved rapidly and released the drug which precipitated out in the dissolution vessel. In contrast, cinnarizine powder showed rapid drug dissolution at low pH, followed by precipitation upon pH change. Oral dosing in rats resulted in a greater than double bioavailability of Eudragit L microparticles compared to the drug powder suspension, although C(max) and T(max) were similar. The higher bioavailability with microparticles contradicts the in vitro results. Such an example highlights that although in vitro results are an indispensable tool for formulation development, an early in vivo assessment of formulation behaviour can provide better prediction for oral bioavailability.
水溶性差的碱性药物对 pH 值变化非常敏感,在酸性胃环境中溶解后,往往会在胃排空时沉淀,从而导致口服生物利用度降低或不稳定。在这项工作中,我们表明,通过将模型难溶性碱性药物(桂利嗪)包封在对 pH 高度敏感的微颗粒(Eudragit L)内,可以提高其口服生物利用度。后者通过乳液溶剂蒸发制备,得到离散的球形微颗粒(直径为 56.4±6.8μm,范围为 1.2±0.3)。预计这些 Eudragit L(溶解阈值 pH 6.0)微颗粒在肠道条件下溶解并释放其药物负荷。因此,尽管桂利嗪在酸性介质中具有高溶解度,但肠溶微颗粒在胃条件下仍能抑制药物的体外释放。在肠道条件下,颗粒迅速溶解并释放出在溶解容器中沉淀的药物。相比之下,桂利嗪粉末在低 pH 值下迅速溶解药物,然后在 pH 值变化时沉淀。在大鼠体内给药时,与药物粉末混悬液相比,Eudragit L 微颗粒的生物利用度提高了一倍以上,尽管 C(max)和 T(max)相似。微颗粒的较高生物利用度与体外结果相矛盾。这样的例子表明,尽管体外结果是制剂开发不可或缺的工具,但早期的体内评估制剂行为可以更好地预测口服生物利用度。